Speaker illustration

Professor Arnoud W J van 't Hof

Maastricht University Medical Centre (MUMC), Maastricht (Netherlands (The))

Member of:

European Society of Cardiology
Association for Acute CardioVascular Care
European Association of Preventive Cardiology

Prof.dr. Arnoud van ‘t Hof is Interventional Cardiologist and head of the department of Interventional Cardiology in Maastricht University Medical Center and Zuyderland Medical Center in Heerlen, the Netherlands. He has a long-standing research history in cardiovascular medicine, particularly in the field of primary angioplasty and ACS, with special interest in pre-hospital diagnosis and triage in the ambulance. He has been (co-) chairing international multi-center clinical trials in this field. He is a board member of the Acute Cardiac Care Association (ACCA) and editorial board member of the European Heart Journal Acute Cardiovascular Care and the Netherlands Heart Journal. He chaired the board of directors of the NCDR, and later the Dutch Heart Registration (NHR) with specific interest for VBHC and data science. He recently joined the EAPC with research on Cardiac Rehabilitation, CV Prevention and Sports Medcine. He has co-authored over 350 publications in peer reviewed journals.

Hypertension and cardiometabolic disorders appear 5–10 years earlier in women with pre-eclampsia

Date: 23 April 2025

Journal: European Journal of Preventive Cardiology

Thumbnail

Prehospital tirofiban increases the rate of disrupted myocardial infarction in patients with ST-segment elevation myocardial infarction: insights from the On-TIME 2 trial

Date: 7 June 2024

Journal: European Heart Journal - Acute CardioVascular Care

Thumbnail

Referral decisions based on a pre-hospital HEART score in suspected non-ST-elevation acute coronary syndrome: final results of the FamouS Triage study

Date: 25 November 2021

Journal: European Heart Journal - Acute CardioVascular Care

Thumbnail

Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y<sub>12</sub> receptor antagonist, in patients with chronic coronary syndromes

Date: 14 November 2019

Journal: European Heart Journal

Thumbnail

ESC 365 is supported by